'Golden time for India to emerge as innovator nation in biopharma sector' Ruchika Sharma23 Jun 2022 10:00 AMWashington: Post COVID19, it's a golden time for India to emerge as an innovator nation in the biopharma sector, organiser of the annual India-US...
Takeda dengue vaccine TAK-003 provides continued protection against dengue fever through 4.5 years in trial Roshni Dhar11 Jun 2022 11:36 AMTakeda has announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic cases, with no...
Health Bulletin 11/6/2022 Roshni Dhar11 Jun 2022 10:57 AMHere are the top health stories for the day:NMC orders crackdown on referral fee, commissions, and online procurement of patients ...
Takeda Dengue vaccine TAK-003 provides continued protection against dengue fever through 4.5 years in trial Ruchika Sharma11 Jun 2022 4:30 AMNew Delhi: Takeda has announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of...
Moderna gets back Spikevax marketing rights in Japan Ruchika Sharma1 Jun 2022 4:30 AMIn Japan, Spikevax is indicated for the prevention of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Novavax partner gets Japenese nod for Nuvaxovid Ruchika Sharma19 April 2022 11:48 AMNovavax licensed and transferred its manufacturing technologies and is supplying the Matrix-M adjuvant to enable Takeda to manufacture the vaccine at...
Takeda appoints Serina Fischer as General Manager for India operations MD Bureau3 March 2022 11:53 AMIn her new role, Serina will lead the company's business in India, ensuring patient access to the company's highly innovative medicines, the drug firm...
Takeda receives USFDA Complete Response Letter for Budesonide Oral Suspension Ruchika Sharma22 Dec 2021 6:00 AMOsaka: Takeda Pharmaceutical Company Limited has announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug...
Takeda Livtencity gets USFDA nod for treatment of post-transplant cytomegalovirus infection Ruchika Sharma24 Nov 2021 7:50 AMLIVTENCITY is a new molecular entity which targets CMV at pUL97, resulting in inhibition of viral DNA replication, encapsidation and nuclear egress.
Takeda's dengue vaccine efficacious, decreases hospitalization in adolescents MD Editorial Team8 Nov 2021 4:30 AMTakeda's live attenuated tetravalent dengue vaccine candidate (TAK-003) will be the first dengue vaccine to be cleared for use in India if approved. ...
Takeda, JCR Pharma join hands to commercialize Hunter Syndrome Therapy Ruchika Sharma3 Oct 2021 4:30 AMOsaka: Takeda Pharmaceutical Company Limited and JCR Pharmaceuticals Co., Ltd. (JCR) have announced a geographically-focused exclusive...
Banking on dengue, COVID-19 shots progress, Takeda CEO eyes vaccine business growth Ruchika Sharma14 Sept 2021 6:30 AMTokyo: Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its...
